A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Clinical trial NCT05305664 · COMPLETED
Trial details
- NCT number
- NCT05305664
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-19
- Primary completion
- 2025-01-28
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.